Figure 1.

CAF co-localize with C39⁺ T cells in the tumor microenvironment. a) Representative staining of CD8⁺ (upper panels) and CD4⁺ (lower panels) T cells from paired non-cancerous lung (NCL) or tumor for CD39 and CD103. b) Proportion of CD8⁺ T cells co-expressing CD39 and CD103 in paired NCL/tumor samples (** P = .005). c) Proportion of CD103-CD39⁺ cells within CD4⁺ T cells from paired NCL and tumor samples (n = 9) (*** P = .0007). d) tSNE plots showing concatenated data files gated on CD45⁺CD3⁺ T cells from four paired NCL and tumor samples, gates indicate the location of CD8⁺CD39⁺ cells, CD4⁺ CD39⁺ cells and CD4⁺ CD103⁺ cells. The distribution of cells derived from non-cancerous lung (NCL) and tumor samples is shown and heat maps illustrate the relative expression of CD103, CD39, PD-1, Tim3 and LAG3. e) The frequency of CD4⁺ cells expressing CD103 in paired NCL and tumor samples (n = 11) (** P = .0075). f). FAP expression on CD45-EpCAM⁻CD31⁻CD90⁺ stromal cells derived from NCL or paired tumor samples (n = 12) (*** P = .0005). g). Representative Immunohistochemistry illustrating localistaion of FAP, CD8, CD39 and CD103 expressing cells in a section of NSCLC, scale bar represents 100 µm. h) Distribution of CD39⁺ and CD103⁺ CD8⁺ T cells illustrates enrichment of CD39⁺ cells within the stroma (*** P = .0008) and CD103⁺ cells within NSCLC tumors (*** P = .006) (n = 6). Two tailed paired T tests were used for all statistical analyses